Noble Financial Weighs in on NanoViricides FY2026 Earnings

NanoViricides, Inc. (NYSE:NNVC) – Stock analysts at Noble Financial issued their FY2026 earnings per share estimates for NanoViricides in a report released on Monday, July 6th. Noble Financial analyst R. Leboyer forecasts that the company will earn ($0.43) per share for the year. Noble Financial currently has a “Outperform” rating and a $6.00 target price on the stock. Noble Financial also issued estimates for NanoViricides’ Q4 2026 earnings at ($0.11) EPS, Q1 2027 earnings at ($0.10) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.13) EPS, FY2027 earnings at ($0.46) EPS, FY2028 earnings at $0.50 EPS and FY2029 earnings at $0.95 EPS.

NanoViricides Trading Down 2.0%

Shares of NYSE NNVC opened at $1.47 on Wednesday. NanoViricides has a 12-month low of $0.85 and a 12-month high of $2.23. The company has a market cap of $33.79 million, a price-to-earnings ratio of -2.04 and a beta of 1.67. The stock’s 50 day simple moving average is $1.46 and its 200 day simple moving average is $1.21.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Armistice Capital LLC acquired a new stake in shares of NanoViricides in the fourth quarter valued at approximately $1,546,000. State Street Corp increased its position in NanoViricides by 29.4% in the 4th quarter. State Street Corp now owns 54,206 shares of the company’s stock valued at $61,000 after acquiring an additional 12,300 shares during the period. Jane Street Group LLC acquired a new stake in NanoViricides in the 4th quarter valued at approximately $140,000. Miller Financial Services LLC bought a new stake in NanoViricides during the 4th quarter valued at $81,000. Finally, Geode Capital Management LLC boosted its position in NanoViricides by 9.4% during the 4th quarter. Geode Capital Management LLC now owns 174,371 shares of the company’s stock worth $197,000 after acquiring an additional 14,944 shares during the period. Institutional investors own 10.30% of the company’s stock.

Key Stories Impacting NanoViricides

Here are the key news stories impacting NanoViricides this week:

• Positive Sentiment: Noble Financial initiated coverage with an Outperform rating and a $6.00 price target, implying substantial upside from current levels and giving investors a bullish valuation anchor. Benzinga
• Positive Sentiment: The firm also issued long-term earnings estimates that turn positive by fiscal 2028 and fiscal 2029, suggesting analysts see a path toward meaningful profitability over time. MarketBeat NNVC
• Neutral Sentiment: NanoViricides said it is advancing NV-387 oral gummies toward a Phase II clinical trial for Ebola in the Democratic Republic of Congo, with a principal investigator and university support already lined up. This keeps the company’s antiviral pipeline in focus, but the trial still depends on regulatory approvals. Access Newswire
• Negative Sentiment: Despite the bullish target, Noble’s near-term estimates still show repeated losses per share through fiscal 2027, which underscores ongoing execution and funding risk for a clinical-stage biotech. MarketBeat NNVC

About NanoViricides

NanoViricides, Inc is a clinical-stage biotechnology company focused on the development of novel antiviral therapies using its proprietary nanomicelle technology. The company designs polymeric, virus-targeted nanoviricides that seek to neutralize viral pathogens by binding to specific viral surface proteins and destroying their structural integrity. NanoViricides’ platform is intended to offer broad-spectrum activity against a range of enveloped viruses, positioning it as a potential solution for both existing and emerging viral threats.

The company’s pipeline includes preclinical and early clinical candidates targeting seasonal and pandemic influenza strains, as well as investigational programs for coronaviruses, hepatitis, dengue, HIV and other viruses.